

Structure–activity relationships of arylbenzofuran H₃ receptor antagonists

Gregory A. Gfesser,* Ramin Faghih, Youssef L. Bennani,[†] Michael P. Curtis,
Timothy A. Esbenshade, Arthur A. Hancock and Marlon D. Cowart

Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories,
100 Abbott Park Road, Abbott Park, IL 60064, USA

Received 1 February 2005; accepted 14 March 2005
Available online 9 April 2005

Abstract—An SAR study of histamine H₃ receptor antagonists based on substituted (*R*)-2-methyl-1-[2-(5-phenyl-benzofuran-2-yl)-ethyl]-pyrrolidines is presented.

© 2005 Elsevier Ltd. All rights reserved.

In the CNS, the histamine H₃ receptor (H₃R) modulates the release of neurotransmitters such as histamine, serotonin, dopamine, and acetylcholine.¹ H₃R antagonists induce the release of these neurotransmitters, and in animal models they have been demonstrated to enhance attention and cognition, and influence feeding, and so may prove useful in the treatment of attention-deficit disorder, Alzheimer's disease, schizophrenia, and obesity.² The efforts of a number of laboratories have been directed toward discovering potent H₃ antagonists for the treatment of these and other indications.^{2b,3}

We previously reported the benzofuran series **1**, where R = CN or C(O)-morpholine, X = CH or N, and a variety of amines were present (Fig. 1).^{3d} One of these analogs, ABT-239 (**2**), was potent in vitro and in animal models showed a desirable pharmacokinetic profile and cognition-enhancing effects at low doses.⁴ To explore the structure–activity relationships of the series and to produce more potent analogs, we prepared a variety of arylbenzofurans bearing a much wider variety of substituents.

Two of the first compounds were prepared in five steps from 4-bromophenol (Scheme 1). After *ortho*-iodination at 0 °C with NaI/NaOCl,⁵ the phenol was cyclized with




Figure 1. Previously reported arylbenzofurans. Values in nanomolar units.


3-buten-1-ol in the presence of copper (I) oxide at 100 °C to afford benzofuran **3**.⁶ This intermediate was then coupled with either 3-cyanophenylboronic acid or 4-fluorophenylboronic acid under Suzuki conditions, the products were mesylated, and then converted to the final products **4a–b** by displacement of the mesylates with (*R*)-2-methylpyrrolidine^{3d} under gentle heating (40 °C). Later, the copper-catalyzed cyclization was replaced by a shorter route, wherein a Sonogashira reaction was run with 1-but-3-ynyl-2-methyl-pyrrolidine to give **5**. In this sequence, the terminal Suzuki reaction allowed a wider variety of aromatic moieties to be readily appended (compounds **4c–x**).

A second route began with a Suzuki reaction⁷ between 4-methoxyphenylboronic acid and 4-bromobenzonitriles to afford **6** (Scheme 1). Demethylation of **6** with BBr₃ at –78 °C gave phenols (4'-bromo-biphenyl-4-ol is commercially available), which were either *ortho*-iodinated

Keywords: Histamine; H₃; Arylbenzofuran.

* Corresponding author. Tel.: +1 847 935 0109; fax: +1 847 937 9195; e-mail: greg.gfesser@abbott.com

[†] Present address: Vertex Pharmaceuticals, Cambridge, MA, USA.




Scheme 1. Reagents: (a) NaOCl, NaI, NaOH, aq MeOH; (b) 3-buten-1-ol, Cu₂O, Py/NMP; (c) ArB(OH)₂, Pd(PPh₃)₄, Na₂CO₃, aq dioxane; (d) (i) MsCl, Et₃N, CH₂Cl₂, (ii) (*R*)-2-methylpyrrolidine tartrate, Cs₂CO₃, MeCN; (e) 325 mesh K₂CO₃, MeCN, 55 °C, sealed bottle 2 days; (f) Pd(OAc)₂, PPh₃, CuI, *i*-Pr₂NH, MeCN; (g) ArB(OH)₂, Pd(PPh₃)₄, Na₂CO₃, H₂O/EtOH/PhH, or, ArB(OH)₂, PdCl₂(PPh₃)₂, Na₂CO₃, aq *i*-PrOH; (h) R¹C₆H₄Br, Pd(PPh₃)₄, Na₂CO₃, H₂O/EtOH/PhH; (j) (i) BBr₃, CH₂Cl₂, (ii) NaOCl, NaI, NaOH, aq MeOH, or NIS, DMF; (k) (2*R*)-1-but-3-ynyl-2-methylpyrrolidine, CuI, Pd(OAc)₂, PR₃, *i*-Pr₂NH, MeCN.


at 0 °C with NaI/NaOCl or at room temperature with NIS (R² = 2-F, 2-Me) to provide intermediates **7**, which were then reacted under Sonogashira reaction conditions to give final target products **8a–g**.

Additional analogs of **4v** were then prepared (Scheme 2). The preparation of alcohols **9–10**, acid **11**, and Weinreb amide **12** have been described.^{4a} This flexible intermediate (**12**) was treated with Grignard reagents (EtMgBr, *i*-BuMgCl, or 3-F-C₆H₄-MgBr) to give the expected ketones **13a–c**. Treatment of **12** with cyclopentyl magnesium bromide afforded a low yield of the unexpected aldehyde **13d**, likely arising from hydride transfer from the Grignard reagent to the nitrile. Target oxime analogs (**14a–d**) were produced by condensation of methylketone **4v** with hydroxylamine at 70 °C or with alkoxamines at 20 °C.

Other target molecules were prepared from **2** or structurally related nitriles **4a** and **8c** (Scheme 2). Cyclopropyl ketones **15a–b** were prepared from the nitriles with cyclopropyl magnesium bromide in the presence of CuI;⁸ in other H₃ antagonists, such as ciproxifan, cyclopropyl ketones have been found to increase potency. Compound **2** was iodinated at the 3-position of the benzofuran ring with NIS in TFA to give **16**. Compound **2** could also be chlorinated with NCS in TFA, to give a four-to-one ratio of chloroarenes **17a** and **17b**. The use of trifluoroacetic acid to protonate the pyrrolidine nitrogen and protect it from oxidation was also important in the synthesis of bromides **18a–b**. Compound **18a** (R¹ = H) was further reacted with several boronic acids under Suzuki conditions to give **19a–f**. Product **19f** was reduced by NaBH₄ to afford **20**.



Scheme 2. Reagents: (a) RMgX, THF; (b) H₂NOR·HCl, Na₂CO₃, MeOH; (c) *c*-PrMgBr, CuI, THF; (d) NIS, TFA; (e) NCS, TFA; (f) Br₂, TFA; (g) ArB(OH)₂, Pd(PPh₃)₄, Na₂CO₃, aq DME; (h) (i) NaBH₄, MeOH, (ii) aq HCl.

Table 1. Binding affinities^a (K_i) of substituted arylbenzofurans at rat cortical H₃ receptors and cloned human H₃ receptors

Compd	Benzofuran substituent	Phenyl substituent	rH ₃ ^c	hH ₃
2 ^b	H	4'-CN	3.2	0.45
4a ^b	H	3'-CN	2.5	0.27
4b	H	4'-F	65	3.2
4c	H	3'-F	17	2.2
4d	H	4'-Cl	82	6.3
4e	H	3'-Cl	48	5.0
4f	H	2'-Cl	24	5.3
4g	H	4'-CF ₃	150	5.7
4h	H	3'-CF ₃	95	3.9
4i	H	4'-Me	160	7.9
4j	H	3'-Me	30	2.7
4k	H	2'-Me	33	4.1
4l	H	4'-OCF ₃	200	7.6
4m	H	3'-OCF ₃	130	11
4n	H	4'-OMe	56	9.1
4o	H	3'-OMe	23	1.2
4p	H	2'-OMe	76	15
4q	H	3'-Cl, 4'-Cl	110	3.6
4r	H	3'-Cl, 5'-Cl	24	5.0
4s	H	3'-Me, 4'-Me	65	5.9
4t	H	3'-Me, 5'-Me	19	3.6
4u	H	4'-COOMe	42	1.9
4v ^b	H	3'-C(O)Me	0.44	0.084
4w ^b	H	4'-CH ₂ OH	4.1	0.88
4x ^b	H	3'-CH ₂ OH	2.8	0.49
8a	H	4'-Br	300	7.7
8b	H	4'-CN, 2'-Me	31	2.0
8c	H	4'-CN, 3'-Me	2.6	0.28
8d	H	4'-CN, 3'-F	9.3	0.64
8e	7-F	4'-CN	5.7	0.43
8f	7-Me	4'-CN	16	1.1
8g	6-Me	4'-CN	4.2	0.77
9 ^b	H	3'-CH(OH)Me	2.8	0.44
10 ^b	H	3'-C(OH)Me ₂	1.3	0.25
11	H	3'-COOH	66	15
12	H	3'-C(O)N(Me)OMe	4.9	0.62
13a ^b	H	3'-C(O)Et	2.3	0.23
13b	H	3'-C(O)CH ₂ CHMe ₂	19	0.68
13c	H	3'-C(O)-(3''-F)C ₆ H ₄	53	2.6
13d	H	3'-CHO	3.3	0.40
14a	H	3'-C(=NOH)Me	3.1	0.49
14b	H	3'-C(=NOMe)Me	4.5	0.42
14c	H	3'-C(=NOEt)Me	51	3.2
14d	H	3'-C(=NO- <i>t</i> -Bu)Me	41	4.3
15a ^b	H	4'-C(O)- <i>c</i> -Pr	6.4	0.26
15b ^b	H	3'-C(O)- <i>c</i> -Pr	2.5	0.21
16	3-I	4'-CN	8.4	0.51
17a	3-Cl	4'-CN	3.7	0.39
17b	3-Cl, 6-Cl	4'-CN	9.7	0.83
18a	3-Br	4'-CN	3.4	0.29
18b	3-Br	4'-CN, 3'-Me	16	1.3
19a	3-Ph	4'-CN	390	21
19b	3-(3'',5''-DiMeC ₆ H ₃)	4'-CN	840	60
19c	3-(3''-Pyridyl)	4'-CN	18	13
19d	3-(2''-Furyl)	4'-CN	42	2.8
19e	3-(3''-Thienyl)	4'-CN	41	2.1
19f	3-(3''(2''CHO)thienyl)	4'-CN	5.8	0.73
20	3-(3''(2''CH ₂ OH)thienyl)	4'-CN	20	1.9

^a Values reported are in nanomolar units, converted from the average of at least three p*K*_i determinations (p*K*_i SEM < 0.25).^b The data for these compounds at *cloned* rat and human H₃Rs has been reported.^{4a}^c The source of rH₃ was membranes from rat cortex.

The synthesized compounds were tested for binding at both the rat cortical (rH₃) and human clonal (hH₃) receptors, with the data shown in Table 1. In every instance H₃ receptor binding was more potent at hH₃ than at rH₃, although SAR trends were similar at hH₃ and rH₃. Because potency was weaker at the rat receptor and because pharmacokinetic assays and behavioral models were to be run in rats, potency at the rat receptor was the primary constraint in choosing compounds for further advancement.

Examination of the in vitro data (Table 1) for SAR revealed that addition of a methyl or halogen to either aromatic ring of **2** did not increase binding. In most cases (**8c–e**, **8g**, **16**, **17a–b**, **18a**) the binding potencies were comparable to the parent or slightly weaker (rH₃ = 2.6–9.7 nM, hH₃ = 0.28–0.83 nM); however, appending a methyl group to either the 2' (**8b**) or 7 (**8f**) positions, or appending both a 3'-methyl and 3-bromo (**18b**) resulted in compounds with greater reductions in potency (rH₃ = 16–31 nM, hH₃ = 1.1–2.0 nM). It was also seen that appending an aromatic ring to position 3 of the benzofuran did not increase binding. Except for one case (**19f**) where binding was similar to the parent **2**, these molecules showed lower affinity for the H₃Rs (**19a–e**, **20**; rH₃ = 18–840 nM, hH₃ = 1.9–60 nM).

Replacement of the nitrile in the parent species with a bromide (**8a**), a fluoride (**4b–c**), one or two chlorides (**4d–f**, **4q–r**) or methyls (**4i–k**, **4s–t**), a trifluoromethyl (**4g–h**) or trifluoromethoxy moiety (**4l–m**), a methoxy group (**4n–p**), a methyl ester (**4u**), or a carboxylic acid (**11**) resulted in compounds with modest to weak binding (rH₃ = 17–300 nM, hH₃ = 1.2–15 nM). The larger, more hydrophobic bromide, trifluoromethyl, and trifluoromethoxy substituents possessed the lowest potencies, and compounds with any of the above groups in position 4' bound less easily to rH₃ than those with groups at position 3' or 2', with the exception of methyl ether **4p**. This trend toward reduced potency extended even to the disubstituted **4q–t**, where 3',4' substitution was weaker than 3',5'. Potency at hH₃ also diminished, but was less affected by these substituents.

Certain molecules with more hydrophilic substitution on the phenyl group—such as ketones and alcohols—bound more tightly to the H₃Rs, and usually showed a decrease in potency as larger hydrophobic groups were

attached. Again, the trend was more pronounced at rH₃ than at hH₃. Oxime **14a** and *O*-methyl oxime **14b** showed higher affinity than the *O*-ethyl and *O*-*t*-butyl analogs **14c–d** for both rH₃ (3.1–4.5 nM vs 41–51 nM) and hH₃ (0.42–0.49 nM vs 3.2–4.3 nM). Larger ketones **13b–c** (rH₃ = 19–53 nM, hH₃ = 0.68–2.6 nM) were less potent than cyclopropyl ketones **15a–b** and ethyl ketone **13a** (rH₃ = 2.3–6.4 nM, hH₃ = 0.21–0.26 nM), which were in turn less potent than the methyl ketone **4v** (rH₃ = 0.44 nM, hH₃ = 0.084 nM). However, the 3'-alcohol series **10** [C(OH)Me₂], **9** [CH(OH)Me], and **4x** [CH₂OH] showed no such trend upon the removal of methyl groups; each possessed a potency similar to **2**, as did nitrile **4a**, amide **12**, and aldehyde **13d** (rH₃ = 1.3–4.9 nM, hH₃ = 0.25–0.62 nM).

It seems likely that some open space exists in the binding pocket around both the benzofuran and phenyl rings, based on the finding that the addition of substituents on either ring (e.g., **4v–x**, **8c–e**, **16–17**, **19f**) can be tolerated. Although the addition of hydrophobic substituents results in compounds which retain (e.g., **8c**, **8g**) or, more frequently, lose (e.g., **8a**, **19a**) potency, the addition of small hydrophilic substituents on the phenyl ring may be advantageous (**4v**, **10**). These data also leave open the possibility that at a short distance from this ring hydrogen-bond acceptors are the species preferred.

The pharmacokinetic (PK) properties of select compounds were also examined (Table 2). Whereas reference compound **2** and its regioisomer **4a** both had good PK in rat,^{4a} another close analog which differed from **2** only by the addition of a methyl group (**8c**) had poor PK, with a low *C*_{max} and AUC p.o., and a bioavailability of only 9%. The most potent compound in the series, **4v**, also gave very poor data in rat. Oral bioavailability was better in dog (*F* = 27%) and very good in monkey (*F* = 72%), and we hypothesized that the high clearance rate of this methyl ketone in rats resulted from rapid hepatic metabolism [as in primary alcohols **4w–x** and oximes **14a–b** (*F*_{rat} = 0–9%)] directed toward the ketone moiety. In order to test this hypothesis, we examined the PK profile of secondary alcohol **9**, tertiary alcohol **10**, and cyclopropyl ketones **15a–b**, and found that each possessed very good bioavailability coupled with both high *C*_{max}s (p.o.) and good AUCs (i.v. and p.o.). Furthermore, both **4a** and **15b** were active in a five-trial inhibitory avoidance model for learning.^{4a}

Table 2. Pharmacokinetic properties of selected arylbenzofurans

Compd	1 mg/kg i.v.				1 mg/kg p.o.			
	<i>t</i> _{1/2} , h	<i>V</i> _β , L/kg	AUC _{0–∞} , ng h/mL	CL _β , L/h kg	<i>C</i> _{max} , ng/mL	<i>t</i> _{1/2} , h	AUC _{0–∞} , ng h/mL	<i>F</i> %
2	5.3	12	673	1.5	29	5.2	349	53
4a	4.3	7.5	835	1.2	27	5.5	320	38
4v	3.0	27	160	8.5	~2	UC	10	6
8c	3.2	11	510	2.0	~8	UC	50	9
9	7.6	23	482	2.1	24	9.4	265	55
10	5.6	21	391	2.6	38	9.0	315	81
15a	9.3	8.2	1649	0.61	31	13	788	48
15b	5.0	6.2	1177	0.86	76	5.1	828	70

Selected data for some of these compounds were previously reported^{4a} but are included to present a more complete profile. UC = uncalculated.

The results here show that among the wide variety of new arylbenzofurans synthesized and described, many of the compounds had nanomolar potency at rat and human H₃ receptors. Good pharmacokinetic properties were found for a subset of the most potent analogs tested, offering the possibility that analogs of **ABT-239** having favorable behavioral efficacy and PK properties could be used to further explore the potential clinical efficacy of H₃R antagonists.

Acknowledgements

We thank John Baranowski, Tracy Carr, Tom Miller, and David Witte for performing binding assays; Kennan Marsh and Jill Wetter for pharmacokinetic analysis; and Gerard B. Fox, Jia Bao Pan, Angela Lewis, and Michael Buckley for conducting behavioral work.

References and notes

- (a) Hill, S. J.; Gannellin, C. R.; Timmerman, H.; Schwartz, J.-C.; Shankley, N. P.; Young, J. M.; Shunack, W.; Levi, R.; Haas, H. L. *Pharmacol. Rev.* **1997**, *49*, 253; (b) Arrang, J.-M.; Garbarg, M.; Schwartz, J.-C. *Nature* **1983**, *302*, 832; (c) Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. *Trends Pharmacol. Sci.* **1998**, *19*, 177; (d) Lovenberg, T. W.; Roland, B. L.; Wilson, S. J.; Jiang, X.; Pyati, J.; Huvar, A.; Jackson, M. R.; Erlander, M. G. *Mol. Pharmacol.* **1999**, *55*, 1101.
- (a) Witkin, J. M.; Nelson, D. L. *Pharmacol. Ther.* **2004**, *103*, 1; (b) Stark, H. *Exp. Opin. Ther. Patents* **2003**, *13*, 851; (c) Halpern, M. T. *Curr. Opin. Cent. Peripher. Nerv. Syst. Invest. Drugs* **1999**, *1*, 524; (d) Ali, S. M.; Tedford, C. E.; Gregory, R.; Handley, M. K.; Yates, S. L.; Hirth, W. W.; Phillips, J. G. *J. Med. Chem.* **1999**, *42*, 903; (e) Leurs, R.; Blandina, P.; Tedford, C.; Timmerman, H. *Trends Pharmacol. Sci.* **1998**, *19*, 177; (f) Hancock, A. A.; Bennani, Y. L.; Bush, E. N.; Esbenshade, T. A.; Faghih, R.; Fox, G. B.; Jacobson, P.; Knourek-Segel, V.; Krueger, K. M.; Nuss, M. E.; Pan, J. B.; Shapiro, R.; Witte, D. G.; Yao, B. B. *Eur. J. Pharmacol.* **2004**, *487*, 183; (g) Fox, G. B.; Pan, J. B.; Esbenshade, T. A.; Bennani, Y. L.; Black, L. A.; Faghih, R.; Hancock, A. A.; Decker, M. W. *Behav. Brain Res.* **2002**, *131*, 151.
- (a) Cowart, M. D.; Altenbach, R. A.; Black, L. A.; Faghih, R.; Zhao, C.; Hancock, A. A. In *Mini-Reviews in Medicinal Chemistry*; Leurs, R., Ed., 2004; *4*, p 997; (b) Mikó, T.; Ligeau, X.; Pertz, H. H.; Arrang, J.-M.; Ganellin, C. R.; Schwartz, J.-C.; Schunack, W.; Stark, H. *Bioorg. Med. Chem.* **2004**, *12*, 2727; (c) Chai, W.; Breitenbucher, J. G.; Kwok, A.; Li, X.; Wong, V.; Carruthers, N. I.; Lovenberg, T. W.; Mazur, C.; Wilson, S. J.; Axe, F. U.; Jones, T. K. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 1767; (d) Cowart, M.; Pratt, J. K.; Stewart, A. O.; Bennani, Y. L.; Esbenshade, T. A.; Hancock, A. A. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 689; (e) Aslanian, R.; wa Mutahi, M.; Shih, N.-Y.; Piwinski, J. J.; West, R.; Williams, S. M.; She, S.; Wu, R.-L.; Hey, J. A. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 1959; (f) Zaragoza, F.; Stephensen, H.; Knudsen, S. M.; Pridal, L.; Wulff, B. S.; Rimvall, K. *J. Med. Chem.* **2004**, *47*, 2833.
- (a) Cowart, M.; Faghih, R.; Curtis, M. P.; Gfesser, G. A.; Bennani, Y. L.; Black, L. A.; Pan, L.; Marsh, K. C.; Sullivan, J. P.; Esbenshade, T. A.; Fox, G. B.; Hancock, A. A. *J. Med. Chem.* **2005**, *48*, 38; (b) Esbenshade, T. A.; Fox, G. B.; Krueger, K. M.; Miller, T. R.; Kang, C. H.; Denny, L. I.; Witte, D. G.; Yao, B. B.; Pan, L.; Wetter, J.; Marsh, K.; Bennani, Y. L.; Cowart, M. D.; Sullivan, J. P.; Hancock, A. A. *J. Pharmacol. Exp. Ther.* **2005**, *313*, 615; (c) Fox, G. B.; Esbenshade, T. A.; Pan, J. B.; Radek, R. J.; Krueger, K. M.; Yao, B. B.; Browman, K. E.; Buckley, M. J.; Ballard, M. E.; Komater, V. A.; Miner, H.; Zhang, M.; Faghih, R.; Rueter, L. E.; Bitner, R. S.; Drescher, K. U.; Wetter, J.; Marsh, K.; Lemaire, M.; Porsolt, R. D.; Bennani, Y. L.; Sullivan, J. P.; Cowart, M. D.; Decker, M. W.; Hancock, A. A. *J. Pharmacol. Exp. Ther.* **2005**, *313*, 176.
- Edgar, K. J.; Falling, S. N. *J. Org. Chem.* **1990**, *55*, 5287.
- Nordvall, G.; Sundquist, S.; Johansson, G.; Glas, G.; Nilvebrant, L.; Hacksell, U. *J. Med. Chem.* **1996**, *39*, 3269.
- Gray, G. W.; Hird, M.; Lacey, D.; Toyne, K. J. *Mol. Cryst. Liq. Cryst.* **1989**, *172*, 165.
- Weiberth, F. J.; Hall, S. S. *J. Org. Chem.* **1987**, *52*, 3901.